Qing-Lei Zeng
Quick facts
Marketed products
- Entecavir + Pegylated interferon α-2b · Virology/Hepatology
This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and pegylated interferon α-2b to enhance immune response against HBV-infected cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: